CellRapeutics™ Leukopak from Myasthenia Gravis Donor (XS-0426-XU254)

Name: CellRapeutics™ Leukopak from Myasthenia Gravis Donor
SKU: XS-0426-XU254
Rating: 5 (1 reviews)

Online Inquiry Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This Leukopak is derived from donors diagnosed with Myasthenia Gravis, providing a high-yield source of cells involved in neuromuscular junction failure. The specimens are rich in B-cell clones producing anti-acetylcholine receptor or anti-MuSK antibodies, alongside supporting follicular T-helper cells. This product is ideal for investigating the loss of B-cell tolerance and the development of antigen-specific depletion therapies for antibody-mediated disorders.

Specific Inquiry

Add to Cart

Donor Information

Product Name
CellRapeutics™ Leukopak from Myasthenia Gravis Donor

Cat. No.
XS-0426-XU254

Donor Age
Young Adult, Senior

Donor Health
Donors present with neuromuscular junction autoimmunity. The leukocyte profile is defined by pathogenic B-cell expansion and T-cell subsets that support autoantibody production against neuronal receptors.

Ethnicity
Diverse backgrounds available.

Anticoagulant
Acid Citrate Dextrose, optimized to preserve the acetylcholine receptor-specific B cell memory and T helper cell function.

Additional Donor Information
Each lot features a Leukopak from donors with confirmed MG. Profiles include Myasthenia Gravis Foundation of America classification and autoantibody status, facilitating research into neuromuscular junction autoimmunity.

Clinical Profile
MGFA clinical classification, autoantibody profile, history of thymectomy, and current use of immunosuppressants or pyridostigmine.

Additional Information

Medication History
Available upon request. Documentation of acetylcholinesterase inhibitors, systemic immunosuppressants, and history of IVIg or therapeutic plasma exchange.

Formulation
Cryopreserved or Fresh options available.

Cell Purity
>90%

Cell Viability
>90%

Mycoplasma Testing
Negative

Sterility Testing
Negative

Genetic Stability Testing
The donor cells maintain their native genetic profile, exhibiting no karyotypic abnormalities or chromosomal instabilities typically associated with prolonged ex vivo expansion.

Application
Drug Discovery, Immuno-oncology Research

Research Use Only
RUO

Quality Control
Each product batch is strictly validated for high cellular viability, specific immune cell counts, and pathogen-free safety, ensuring consistent clinical phenotypes and ethical compliance for advanced immunological research.

Storage
Store fresh Leukopaks at 2°C to 8°C for immediate use, cryopreserved samples must be kept in liquid nitrogen vapor phase below -150°C.

Shiping
Dry Ice

Handling Notes
Process fresh cells within 48 hours or perform rapid thawing of cryovials in a 37°C water bath followed by gradual dilution to maximize recovery.

Warnings
Treat as potentially biohazardous human-derived material and handle strictly under BSL-2 guidelines using appropriate personal protective equipment.

Size
Full Bag, Half Bag

Keywords
CellRapeutics™ Leukopak from Myasthenia Gravis Donor, Leukopak, Myasthenia Gravis

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for CellRapeutics™ Leukopak from Myasthenia Gravis Donor (XS-0426-XU254). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.